Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Replimune Group stock

Learn how to easily invest in Replimune Group stock.

Replimune Group is a biotechnology business based in the US. Replimune Group shares (REPL) are listed on the NASDAQ and all prices are listed in US Dollars. Replimune Group employs 284 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy Replimune Group stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – REPL. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 in stock when you fund a new account within 30 days

Promoted for social trading

Finder Award


  • Easy to use platform with $0 stock trading & no annual fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100

Promoted for active trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

Replimune Group stock price (NASDAQ: REPL)

Use our graph to track the performance of REPL stocks over time.

Replimune Group shares at a glance

Information last updated 2023-09-17.
Latest market close$16.78
52-week range$15.07 - $29.52
50-day moving average $20.73
200-day moving average $21.62
Wall St. target price$50.30
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.76

Buy Replimune Group stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 7 of 7
Name Product Ratings Available asset types Minimum deposit Signup bonus
SoFi Invest
Finder Rating: 4.6 / 5: ★★★★★

Finder Award
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000 in stock
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Rating: 4.2 / 5: ★★★★★

Finder Award
Stocks, Options, ETFs, Cryptocurrency
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Finder Rating: 4.1 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
Finder Rating: 4 / 5: ★★★★★
Stocks, ETFs, Cryptocurrency, Art, Treasury Bills, Collectibles
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
2.5% fee applies to all alternative asset transactions.
Finder Rating: 4.2 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4.9% interest on uninvested cash in your account with Robinhood Gold.
JPMorgan Self-Directed Investing
Finder Rating: 4 / 5: ★★★★★
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
Get $50 - $700
when you open and fund an account with $5,000 - $250,000+
Pay no commissions on stocks, ETFs, mutual funds and options.
Finder Rating: 4 / 5: ★★★★★
Stocks, ETFs
Wealthfront builds a free financial plan for the life you want and automate your investments at a low cost.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy Replimune Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Replimune Group price performance over time

Historical closes compared with the close of $16.78 from 2023-09-22

1 week (2023-09-15) -6.20%
1 month (2023-08-24) -17.79%
3 months (2023-06-23) -29.58%
6 months (2023-03-24) -15.17%
1 year (2022-09-23) 5.67%
2 years (2021-09-24) -47.99%
3 years (2020-09-24) 20.64
5 years (2018-09-24) 19.19

Replimune Group financials

Gross profit TTM $0
Return on assets TTM -22.26%
Return on equity TTM -39.29%
Profit margin 0%
Book value $8.72
Market Capitalization $1.2 billion

TTM: trailing 12 months

Replimune Group share dividends

We're not expecting Replimune Group to pay a dividend over the next 12 months.

Replimune Group share price volatility

Over the last 12 months, Replimune Group's shares have ranged in value from as little as $15.068 up to $29.5229. A popular way to gauge a stock's volatility is its "beta".

REPL.US volatility(beta: 1.66)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Replimune Group's is 1.6578. This would suggest that Replimune Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Replimune Group overview

Replimune Group, Inc. , a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Frequently asked questions

What percentage of Replimune Group is owned by insiders or institutions?
Currently 8.315% of Replimune Group shares are held by insiders and 94.994% by institutions.
How many people work for Replimune Group?
Latest data suggests 284 work at Replimune Group.
When does the fiscal year end for Replimune Group?
Replimune Group's fiscal year ends in March.
Where is Replimune Group based?
Replimune Group's address is: 500 Unicorn Park Drive, Woburn, MA, United States, 01801
What is Replimune Group's ISIN number?
Replimune Group's international securities identification number is: US76029N1063
What is Replimune Group's CUSIP number?
Replimune Group's Committee on Uniform Securities Identification Procedures number is: 76029N106

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site